Needham Reiterates Buy on Clearside Biomedical, Maintains $4 Price Target
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Serge Belanger has reiterated a 'Buy' rating on Clearside Biomedical (NASDAQ:CLSD) and maintained a $4 price target.
August 15, 2023 | 10:45 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Serge Belanger has reiterated a 'Buy' rating on Clearside Biomedical and maintained a $4 price target.
The reiteration of a 'Buy' rating by a Needham analyst and the maintenance of a $4 price target indicates a positive outlook for Clearside Biomedical. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100